Changes in the oculas surface after hypotensive surgery

Abstract

BACKGROUND: Hundreds of studies are dedicated to the negative effects of glaucoma therapy on the ocular surface. At the same time, the state of the eye surface after successful hypotensive surgery, which resulted in the cessation or significant reduction of medical therapy, has not been studied.

AIM: To identify ocular surface changes after glaucoma surgery.

MATERIALS AND METHODS: The study group consisted of 475 consecutively enrolled patients who were operated during 2016–2020 in Saint Petersburg Multidisciplinary City Hospital No. 2 for primary open-angle unstable glaucoma, and then observed for 6 to 24 months. Trabeculectomy (TE) was used as the first hypotensive procedure (418 patients), as re-operation — TE (25 patients) or Ahmed valve implantation (32 patients) were chosen. Using statistical methods, the dynamics of symptoms (OSDI) and signs [tear film break-up time (TBUT) and reflex tear production defined by Schirmer I test] depending on outcome (“complete” or “partial” success and “total failure”) were analyzed.

RESULTS: The cessation of the pharmacological load due to the “complete success” of the surgery was accompanied by pronounced (two-fold) and long (for at least two years) decrease of OSDI scores. The obliged, even partial, return to instillations by patients, who were included into the subgroup of “partial success”, within six months, transformed the achieved differences into insignificant ones. TBUT at “complete” and “partial success” significantly increased at all end-points of the study, significantly differing from the similar indicator in the subgroup “total failure”. The results of the Schirmer I test against the background of “complete success” of the operation showed a statistically significant increase, compared to the baseline , delayed for six months, throughout the whole further follow-up period. Patients entering the “partial success” subgroup in 24 months after surgery, also showed a significant increase in tear secretion. The failure of glaucoma surgery was accompanied by a brief and insignificant improvement in all scores.

CONCLUSIONS: The hypotensive surgery, which lead to “complete success”, was accompanied by a significant improvement of the ocular surface state. Restart of local therapy reduces achieved results. Failure of surgical treatment is associated with minimal fluctuations of the studied parameters.

Keywords

glaucoma / trabeculectomy / Ahmed valve implantation / ocular surface / dry eye syndrome / preservative load / OSDI / tear film break-up time / TBUT / Norn test / Schirmer I test

References

[1] Brzheskiy VV. Glaukoma i sindrom “sukhogo glaza”. Moscow: Borges, 2018. 228 p. (In Russ.)

[2] Бржеский В.В. Глаукома и синдром «сухого глаза». Москва: Боргес, 2018. 228 c.

[3] Antonova AV, Nikolaenko VP, Brzheskiy VV. Realization of a cascade treatment algorithm for glaucoma in St. Petersburg. Russian Journal of Clinical Ophthalmology. 2021;21(3):123–128. (In Russ.) DOI: 10.32364/2311-7729-2021-21-3-123-128

[4] Антонова А.В., Николаенко В.П., Бржеский В.В. Реализация «каскадного» алгоритма лечения глаукомы в Санкт-Петербурге // Клиническая офтальмология. 2021. T. 21, № 3. C. 123–128. DOI: 10.32364/2311-7729-2021-21-3-123-128

[5] Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543–1548. DOI: 10.1001/archopht.1990.01070130045027

[6] Lavin M.J., Wormald R.P.L., Migdal C.S., Hitchings R.A. The influence of prior therapy on the success of trabeculectomy // Arch Ophthalmol. 1990. Vol. 108, No. 11. P. 1543–1548. DOI: 10.1001/archopht.1990.01070130045027

[7] Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1454. DOI: 10.1001/archopht.1994.01090230060021

[8] Broadway D.C., Grierson I., O’Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery // Arch Ophthalmol. 1994. Vol. 112, No. 11. P. 1446–1454. DOI: 10.1001/archopht.1994.01090230060021

[9] Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437–1445. DOI: 10.1001/archopht.1994.01090230051020

[10] Broadway D.C., Grierson I., O’Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile // Arch Ophthalmol. 1994. Vol. 112, No. 11. P. 1437–1445. DOI: 10.1001/archopht.1994.01090230051020

[11] Holló G, Schmidl D, Hommer A. Referral for firstglaucoma surgery in Europe, the ReF-GS study. Eur J Ophthalmol. 2019;29(4) 406–416. DOI: 10.1177/1120672118791937

[12] Holló G., Schmidl D., Hommer A. Referral for firstglaucoma surgery in Europe, the ReF-GS study // Eur J Ophthalmol. 2019. Vol. 29, No. 4. P. 406–416. DOI: 10.1177/1120672118791937

[13] Avo-portal.ru [Internet]. Klinicheskie rekomendatsii. Glaukoma pervichnaya otkrytougol’naya [cited 2023 Mar 7]. Available at: http://avo-portal.ru/doc/fkr/item/246-glaukoma-otkrytougolnay (In Russ.)

[14] Avo-portal.ru [Электронный ресурс]. Клинические рекомендации. Глаукома первичная открытоугольная [дата обращения: 07.03.2023]. Доступ по: http://avo-portal.ru/doc/fkr/item/246-glaukoma-otkrytougolnay

[15] Erichev VP, Petrov SYu, Antonov AA, Volzhanin AV. International standards of clinical trials in glaucoma surgery. National Journal glaucoma. 2016;15(2):102–112. (In Russ.)

[16] Еричев В.П., Петров С.Ю., Антонов А.А., Волжанин А.В. Международные стандарты проведения клинических исследований по хирургии глаукомы // Национальный журнал глаукома. 2016. T. 15, № 2. C. 102–112.

[17] Shaarawy T, Grehn F, Sherwood M. Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association. Amsterdam: Kugler Publications, 2009.

[18] Shaarawy T., Grehn F., Sherwood M. Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association. Amsterdam: Kugler Publications, 2009.

[19] Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: A review. Open Ophthalmol J. 2014;8:67–72. DOI:10.2174/1874364101408010067

[20] Actis A.G., Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: A review // Open Ophthalmol J. 2014. Vol. 8. P. 67–72. DOI:10.2174/187436410140801 0067

[21] Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):279–1289. DOI: 10.1080/17425255.2016.1209481

[22] Aguayo Bonniard A., Yeung J.Y., Chan C.C., Birt C.M. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) // Expert Opin Drug Metab Toxicol. 2016. Vol. 12, No. 11. P. 1279–1289. DOI: 10.1080/17425255.2016.1209481

[23] Baudouin C. Ocular Surface and External Filtration Surgery: Mutual Relationships. Dev Ophthalmol. 2017;59:67–79. DOI: 10.1159/000458487

[24] Baudouin C. Ocular Surface and External Filtration Surgery: Mutual Relationships // Dev Ophthalmol. 2017. Vol. 59. P. 67–79. DOI: 10.1159/000458487

[25] Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. DOI: 10.1016/j.jtos.2017.05.011

[26] Bron A.J., de Paiva C.S., Chauhan S.K., et al. TFOS DEWS II pathophysiology report // Ocul Surf. 2017. Vol. 15, No. 3. P. 438–510. DOI: 10.1016/j.jtos.2017.05.011

[27] Sheppard JD, Nichols KK. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. Ophthalmol Ther. 2023; In Press. DOI: 10.1007/s40123-023-00669-1

[28] Sheppard J.D., Nichols K.K. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape // Ophthalmol Ther. 2023. In Press. DOI: 10.1007/s40123-023-00669-1

[29] Bartlett JD, Keith MS, Sudharshan L, Snedecor S. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;9:1719–1730. DOI: 10.2147/OPTH.S89700

[30] Bartlett J.D., Keith M.S., Sudharshan L., Snedecor S. Associations between signs and symptoms of dry eye disease: a systematic review // Clin Ophthalmol. 2015. Vol. 9. P. 1719–1730. DOI: 10.2147/OPTH.S89700

[31] Baudouin C, Rolando M, Benitez Del Castillo JM, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res. 2019;71:68–87. DOI: 10.1016/j.preteyeres.2018.11.007

[32] Baudouin C., Rolando M., Benitez Del Castillo J.M., et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases // Prog Retin Eye Res. 2019. Vol. 71. P. 68–87. DOI: 10.1016/j.preteyeres.2018.11.007

[33] Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81. DOI: 10.3238/arztebl.2015.0071

[34] Messmer E.M. The pathophysiology, diagnosis, and treatment of dry eye disease // Dtsch Arztebl Int. 2015. Vol. 112, No. 5. P. 71–81. DOI: 10.3238/arztebl.2015.0071

[35] Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283. DOI: 10.1016/j.jtos.2017.05.008

[36] Craig J.P., Nichols K.K., Akpek E.K., et al. TFOS DEWS II Definition and Classification Report // Ocul Surf. 2017. Vol. 15, No. 3. P. 276–283. DOI: 10.1016/j.jtos.2017.05.008

[37] Tsubota K, Pflugfelder SC, Liu Z, et al. Defining Dry Eye from a Clinical Perspective. Int J Mol Sci. 2020;21(23):9271. DOI: 10.3390/ijms21239271

[38] Tsubota K., Pflugfelder S.C., Liu Z., et al. Defining Dry Eye from a Clinical Perspective // Int J Mol Sci. 2020. Vol. 21, No. 23. ID9271. DOI: 10.3390/ijms21239271

[39] Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348–361. DOI: 10.1097/ICU.0000000000000768

[40] Mittal R., Patel S., Galor A. Alternative therapies for dry eye disease // Curr Opin Ophthalmol. 2021. Vol. 32, No. 4. P. 348–361. DOI: 10.1097/ICU.0000000000000768

[41] Periman LM, Perez VL, Saban DR, et al. The Immunological basis of Dry Eye Disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. DOI: 10.1089/jop.2019.0060

[42] Periman L.M., Perez V.L., Saban D.R., et al. The Immunological basis of Dry Eye Disease and current topical treatment options // J Ocul Pharmacol Ther. 2020. Vol. 36, No. 3. P. 137–146. DOI: 10.1089/jop.2019.0060

[43] Rao SK, Mohan R, Gokhale N, et al. Inflammation and dry eye disease-where are we? Int J Ophthalmol. 2022;15(5):820–827. DOI: 10.18240/ijo.2022.05.20

[44] Rao S.K., Mohan R., Gokhale N., et al. Inflammation and dry eye disease-where are we? // Int J Ophthalmol. 2022. Vol. 15, No. 5. P. 820–827. DOI: 10.18240/ijo.2022.05.20

[45] Аntonova АV, Nikolaenko VP, Brzheskiy VV, Vuks AJ. Factors influencing the effectiveness of trabeculectomy: following materials of the City Multidisciplinary Hospital No. 2. Ophthalmology Reports. 2022;15(4):35–44. (In Russ.) DOI: 10.17816/OV159363

[46] Антонова А.В., Николаенко В.П., Бржеский В.В., Вукс А.Я. Факторы, снижающие эффективность синустрабекулэктомии: по материалам Санкт-Петербургского городского офтальмологического центра // Офтальмологические ведомости. 2022. Т. 15, № 4. С. 35–44. DOI: 10.17816/OV159363

RIGHTS & PERMISSIONS

Аntonova А.V., Nikolaenko V.P., Brzheskiy V.V., Vuks A.J.